CEO, Renexes LLC, ex-President, Mundipharma Japan and Solasia Pharma
Steve brings over 20 years of senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 2014, he established his own biopharma consultancy, and continues to support Japanese, Chinese, and western biopharma clients. From 2014 until May 2018, Steve was Managing Director and Head of Asia for Locust Walk, where he established the Locust Walk Japan office. During the four years that Steve ran the Locust Walk Japan office, he oversaw eleven transactions (including buy-side and sell-side transactions) between western and Asian companies.
Steve previously headed the Japanese operations of Shire Pharmaceuticals. Before Shire, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. Raising over $40MM in venture capital, he built a portfolio of novel cancer drugs and established operations in Japan and China. Steve launched his biopharma career at Purdue Pharma in business development, and then held the position of President of Mundipharma Japan for nine years. In this role, he oversaw the development and commercialization of the company’s leading pain management franchise.
Steve, his wife, and two daughters currently have their primary residence in Bellevue, Washington. Steve is fluent in written and spoken Japanese.
Corporate Advisor of Seed Planning, Representative of HMIC, Representative of Ryu no Senaka
Kazumi Fujikawa is well known in the “insight professional circle” for her distinguished experience that includes global, regional and local roles for various multinational corporation: Takeda, Pfizer, IQVIA and Sanofi. She is active promoting the values of Insight roles (Market Research, Competitive Intelligence and Forecasting etc.) by establishing HMIC (Healthcare Market Intelligence Community) and worked together with the network of Insight society in Europe and US. She is also active for the regional revitalization project of her birth place: Innoshima, Onomichi city.
She holds BA of English Literature, Notre Dame Seishin University, Japan and holds MBA, Marketing from Leicester University, UK. She is certified in leadership and organizational development from New York University. She is a certified MBTI instructor and National Licensed Career Consultant.
She is currently working as a corporate advisor of Seed Planning, the representative of HMIC and the representative of Ryu no Senaka (Innoshima Revitalization Project)
CEO, Hamano International
He is a recipient of the U.S. FDA Commissioner's Special Award and a former ICHGMP EWG member and received his PhD from the University of Tokyo and his Master's degree from Kanazawa University, in pharmacy, a registered Pharmacist, involved in new business development, technology transfer, licensing, negotiation, contract drafting, JV establishment, and M&A for 25 years in big pharma.
His areas of expertise include licensing, technology transfer, new business development, start-up consulting and related services, currently serves as an adviser to the Toyama Pharmaceutical Association. He also served as the Senior Vice President of KUTLO-NITT (TLO Union), as CD of Hokuriku Innovation Cluster for Health Science and adviser to the DBJ VC "BHP".
He has visited more than 250 venture companies in the world and made business contacts with more than 350 leading pharmaceutical companies in Japan and overseas. Traveled overseas more than 300 times.
Office is located in Nihonbashi, Tokyo, the center of Japan's pharmaceutical industry.
Former Representative Director and President & CEO of KYORIN Pharmaceutical, Director (Outside) of Fuji Pharma, Program Officer and Committee member of AMED, Visiting Professor, Kitasato University, Ph. D. (School of Medicine)
Dr Keiji Hirai joined KYORIN Pharmaceutical Co., Ltd. in April 1972. He was appointed Executive Director, Discovery Research Headquarters of KYORIN Pharmaceutical Co., Ltd. in 2002 and Director of ActivX Biosciences, Inc. (SanDiego) from 2004 to 2012. In 2009, he became the Representative Director and President & CEO, R&D Headquarters and Business Development of KYORIN Pharmaceutical Co., Ltd. and Executive Director of KYORIN Co., Ltd. In 2013, he was appointed Advisor of KYORIN Pharmaceutical Co., Ltd.
Dr Hirai is currently the Director (Outside) of Fuji Pharma Co., Ltd., Program Officer, Department of Research Promotion Division of Infectious Disease Research of Japan Agency for Medical Research and Development (AMED), Committee member (Department of CiCLE Innovation) of AMED, and a Visiting Professor, the Omura Satoshi Memorial Institute, Kitasato University.
He received his Ph. D. from Gunma University (School of Medicine) in May 1987.
Managing Director, Zinagi Consulting
Thomas established Zinagi, a lifescience consulting company, in 2013 and has successfully supported innovative medical device, medical software, and biotech companies. Thomas previously served as Lifescience Ambassador for Medicon Valley Alliance and prior to that held commercial positions at several global big pharma companies.
Professor, University of Tokyo/Graduate School of Frontier Sciences
Shingo Kano is a Professor in Bio-Innovation Policy Unit, Graduate school of Frontier Science, the University of Tokyo, where he also completed his PhD in Science Policy. He had a varied career in industry as management consultant in Nomura Research Institute, securities analyst and venture capitalist for the healthcare sector in Nomura Securities and run the university spin off drug discovery firm as president and CEO for ten years before starting his academic career.
His current research focuses on the recognition gap between university and industry, the role and management of university spin off, how regulation and innovation interact in the advanced industries, and the changing role of universities and companies in the national innovation systems.
Editor-in-Chief, Nikkei Biotechnology &Business, Nikkei Business Publications, Inc.
In 2002, graduated from the Faculty of Agriculture, Tokyo University of Agriculture and Technology, and joined Nikkei Business Publications. For seven years, starting in 2002, Kubota collected information and wrote articles about the bio- and healthcare industry inside and outside Japan as a reporter for a monthly magazine, Nikkei Biotechnology & Business (now discontinued), and a newsletter, Nikkei Biotech . In 2009 and after, Kubota collected information and wrote articles about end-of-life care, novel influenza, the Great East Japan Earthquake, and other topics as a reporter for Nikkei Medical, which is a magazine for physicians. Since 2014, Kubota has served as deputy editor of Nikkei Biotechnology & Business and deputy editor of Nikkei Medical. Since April 2023, Kubota has been in her current position and conducts research and writes articles focusing on the diversification of modalities in the pharmaceutical industry.
CEO, Miyata Institute of Technologies/President, Healthcare Innovation
Mr. Miyata joined Nikkei Inc. in 1979 after completing a postgraduate degree in Botany at the University of Tokyo. Mr. Miyata then worked in the editorial department of Nikkei medical and was involved in the launch of Nikkei biotech. Mr. Miyata was then appointed as the Editor-in-Chief of Nikkei biotech in 1985. In July 2015, Mr. Miyata founded the Miyata Institute of Technologies and became the President. Then in April 2017, he founded Healthcare Innovation and was appointed it’s President.
He is also involved in various public activities such as being the Ministry of Health, Labour and Welfare and AMED.
Professor, Faculty of Science and Engineering, Waseda University, and the Waseda University Center for Advanced Biomedical Sciences | President of DEN Medical Corporation MIH Clinic | MD. Ph. D.; surgical specialist of Japan Surgical Society; industrial physician; Japan Health Conference executive committee member
In 1999, Miyata transferred into the Faculty of Medicine, Osaka University, in the third year, following his assignment to a laboratory related to medical-engineering cooperation at the School of Science and Engineering, Waseda University. In 2003, he joined the First Surgery Department of Osaka University. In 2009, Miyata faced issues related to drug lag and device lag on the medical front as a physician, joined the Ministry of Health, Labour and Welfare, and was involved in many healthcare reforms to establish rules for the practical use of pharmaceutical products, medical devices, and regenerative medicine.
He was engaged in restoration and recovery from the Great East Japan Earthquake as well. Miyata is still a working surgeon and regularly performs operations. At the same time, he is also promoting the establishment of community-based integrated care systems. To promote homecare, Miyata founded the MIH Clinic. Miyata engages in the protection of community healthcare, as well as company health management, and is active in the prevention of the deterioration of lifestyle-related diseases, and in home healthcare, daycare for sick children, online medical care, and COVID-19 measures.
Miyata is familiar with drug administration, as he was also in charge of the Investigational Committee for Usage of Unapproved/Off-label Drugs, advanced medical care, and measures against drug-induced damage while he was in the Ministry of Health, Labour and Welfare. Miyata engages in multifaceted activities to respond to the needs of the times, for example, by establishing a self-medication digital business in which physicians collaborate with pharmacists using a smartphone-based application.
In Miyata's laboratory of Waseda University, he is studying healthcare policy, regulatory science, online medical care/software/SaMD, healthcare/medical care DX, including the use of PHR and data, clinical research, clinical epidemiology, clinical study, PMD Acts, regenerative medicine system, medical insurance system, clinical examination, foods with function claims, etc. Moreover, Miyata promotes the development of human resources for clinical epidemiology as the Board member of the Society for Clinical Epidemiology.
Professor, the Division of Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences, Ph. D. (Clinical Biostatistics), Pharmacist
Dr. Mamoru Narukawa graduated from the Tokyo University, Faculty of Pharmaceutical Sciences, and joined the New Drugs Division, Ministry of Health and Welfare in 1991. Since then he has experienced several posts concerning new drug review/approval, pharmaceutical regulation and policy reforms, and medical insurance system including drug pricing. He became an Associate Professor in the Division of Pharmaceutical Medicine, Kitasato University Graduate School of Pharmaceutical Sciences in 2007, and assumed the position of the Professor in 2016. His specialties are clinical trials, pharmaceutical regulations, and biostatistics.
Senior Analyst/Director, Credit Suisse Securities
After graduating from Arizona State University with a degree in Finance, Mr. Sakai joined Imperial Chemical Industries Japan, a British chemical company, where he worked for five years in Japan and the UK. Mr. Sakai then joined the Corporate Research Department of the Economic Research Institute of Yamaichi Securities. After this, Mr. Sakai joined Société Générale, working within Domestic Equities and the Corporate Research Department in 1998. Since 2002, he has worked as an analyst for the pharmaceutical industry in Deutsche Securities' Equities Research Department. Mr. Sakai joined Credit Suisse First Boston Securities (now Credit Suisse Securities (Japan) Limited) in July 2005 where he worked as a Senior Analyst and Director in the Equity Research Department. In both 2008 and 2009, Mr. Sakai was ranked third in the pharmaceutical sector by Institutional Investor magazine. He is a member of the Securities Analysis Association of Japan. He is also the author of several books.
Professor, Graduate School of Health Innovation, Kanagawa University of Human Services, MBA., DrMedSci
Dr Hiroyuki Sakamaki is the professor for Graduate School of Health Innovation, Kanagawa University of Human Services. He taught at many schools around Japan, including Keio University, Meijo University, and Tokyo University of Science. He was also the chief research scientist for the Institute for Health Economics and Policy (IHEP) that is a non-profit organization established by the Ministry of Health, Labour and Welfare (MHLW). He is an expert for the health technology assessment in Japan holding an MBA and a doctorate degree in medical science. He conducts cost effectiveness analyses related to medical technologies in order to develop useful efficacy indicators.
Additionally, he specializes in research on pharmaceutical industry policies where he analyzes reimbursement of medicines and medical devices from a health economics perspective, and investigates environmental factors surrounding pharmaceutical and device companies. He has acted as chief researcher on several projects relating to advanced therapies such as biologics and has led research on generics and biosimilar use.
He is an active member of various health policy committees established by the MHLW. He works research projects related to pharmaceutical policy, most of the researches are used as the basis for the discussion of healthcare system reforms.
Deputy Director of National Cancer Center Hospital, Director / Clinical Research Support Office, Director / Department of Experimental Therapeutics
Dr. Yamamoto graduated from Hiroshima University School of Medicine in 1991 and started his residency in internal medicine at the National Cancer Center Hospital in 1995. Dr. Yamamoto became a physician in the Department of Respiratory Medicine at the National Cancer Center Hospital in 2000, and in 2013 he progressed to Director of the Department of Advanced Medicine there. Since 2019, Dr Yamamoto has worked as the Director of the Division of Clinical Research Support and Deputy Director of the National Cancer Center Hospital. Dr Yamamoto specializes in the early clinical development of novel anticancer agents, thoracic oncology and clinical pharmacology. Dr. Yamamoto received the ASCO Merit Award in 1996, 1999 and 2000, and has been a member of the editorial board of the Japanese Journal of Clinical Oncology since 2005.